Missense mutations in fibroblast growth factor receptor 3 (FGFR3) result in several types of human skeletal dysplasia, including the neonatally lethal dwarfism known as thanatophoric dysplasia. An engineered Ser 365 →Cys substitution in mouse FGFR3, which is equivalent to a mutation associated with thanatophoric dysplasia-I in humans, has now been shown to cause severe dwarfism but not neonatal death. The mutant mice exhibit shortened limbs as a result of markedly reduced proliferation and impaired differentiation of growth plate chondrocytes. The receptor-activating mutation also resulted in downregulation of expression of the Indian hedgehog (IHH) and parathyroid hormone-related protein (PTHrP) receptor genes, both of which are important for bone growth. Interactions between FGFR3-and PTHrP-receptor-mediated signals during endochondral ossification were examined with embryonic metatarsal bones maintained in culture under defined conditions. Consistent with the in vivo observations, FGF2 inhibited bone growth in culture and induced downregulation of IHH and PTHrP receptor gene expression. Furthermore, PTHrP partially reversed the inhibition of long bone growth caused by activation of FGFR3; however, it impaired the differentiation of chondrocytes in an FGFR3-independent manner. These observations suggest that FGFR3 and IHH-PTHrP signals are transmitted by two interacting parallel pathways that mediate both overlapping and distinct functions during endochondral ossification.
INTRODUCTION
Vertebrate long bones are formed by endochondral ossification, which involves the production of cartilage tissue through mesenchymal cell condensation and its subsequent replacement by bone. During this highly coordinated process, chondrocytes undergo programmed cell proliferation, differentiation, death and replacement by osteoblasts (1) .
Endochondral ossification is regulated by many growth factors and signaling molecules, including fibroblast growth factor receptor 3 (FGFR3), Indian hedgehog (IHH), parathyroid hormone-related protein (PTHrP) and its receptor (PTHrP-R), STAT (signal transducer and activator of transcription) proteins, and cell cycle inhibitors (2) (3) (4) (5) (6) (7) (8) . FGFR3 is one of four membrane-spanning tyrosine kinase receptors that mediate signals of at least 21 FGFs (9, 10) . This receptor was first implicated in bone growth by the observation that a Gly→Arg missense mutation (G380R) in its transmembrane domain results in achondroplasia, the most common form of dwarfism in humans (11, 12) . Many additional mutations in various regions of FGFR3 were subsequently shown to cause skeletal dysplasias of varying severity, including hypochondroplasia, severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN) and thanatophoric dysplasia (TD) (13) (14) (15) (16) .
TD is the most severe form of dwarfism caused by FGFR3 mutations (14) . Affected individuals exhibit markedly shortened limbs and generally die of respiratory failure within a few hours after birth. The two distinct types of TD are distinguished clinically by the presence of straight femurs and cloverleaf skull (TD-II) or curved short femurs (TD-I). TD-II is caused by a K650E mutation in the tyrosine kinase domain of FGFR3, whereas several different point mutations, including R248C, S249C, S371C, Stop807G, Stop807R and Stop807C, cause TD-I (15, (17) (18) (19) . Most individuals with TD-I harbor the R248C mutation, with the other mutations occurring less frequently (19, 20) .
FGFR3 mutations examined so far result in ligand-independent phosphorylation of the tyrosine kinase domain (5, (21) (22) (23) . Furthermore, the FGFR3-TD-II mutation activates STAT proteins both in vivo and in vitro (7) . This results in upregulation of cell cycle inhibitors that block chondrocyte proliferation and retard bone growth, as demonstrated recently for mutations that cause achondroplasia and TD-II (5-7). Expression of IHH is also reduced in dwarf mice expressing activated FGFR3 (6, 24) , suggesting that signaling through FGFR3 negatively regulates IHH expression.
Given that both FGF-FGFR3 and IHH-PTHrP signals play important roles in chondrocyte proliferation and differentiation and that FGFR3 signaling appears to downregulate the expression of IHH (2) (3) (4) (25) (26) (27) , it is possible that these two pathways interact functionally during endochondral bone growth. To shed light on such interactions and their role in skeletal dysplasia, as well as generating mouse models representing various FGFR3 mutations, we introduced an S365C mutation, which corresponds to the TD-I-associated S371C mutation in human FGFR3, into the mouse genome using gene targeting. The heterozygous mutant mice were unexpectedly viable and exhibited skeletal dysplasia similar to, but more severe than, human achondroplasia. Unlike previously described achondroplastic mice (5, 6, 24, 28, 29) , the FGFR3-S365C mutant animals also exhibited skeletal dysplasia at embryonic stages, making it possible to study molecular interactions in explant cultures of embryonic bone. Using this culture system, we have demonstrated that decreased endochondral bone growth caused by activated FGFR3 or basic FGF (bFGF) treatment is accompanied by downregulation of IHH and PTHrP-R gene expression, suggesting a role for IHH-PTHrP-PTHrP-R signaling in FGFR3-associated skeletal dysplasias. Moreover, our data suggest that FGF-FGFR3 signaling inhibits chondrocyte proliferation through the regulation of IHH expression, and that FGF-FGFR3 and PTHrP-PTHrP-R independently inhibit chondrocyte differentiation.
RESULTS

The S365C mutation of FGFR3 results in viable dwarf mice
To study the effect of the S365C mutation of FGFR3 on bone growth, we introduced the mutation into the mouse genome (Fig. 1) . Because the presence of the neo gene in intron 10 prevented normal splicing of the mutant Fgfr3 gene (data not shown), resulting in a phenotype resembling that of FGFR3 knockout mice (3), we crossed the heterozygous mutant animals with EIIa-Cre mice (30) to excise the neo sequence from the germline (Fig. 1B) . After removal of the neo gene, the mutant allele was expressed at the same level as was the wildtype allele, as revealed by northern blot analysis (data not shown). All data presented below were obtained from mice lacking the neo gene.
At birth, mice heterozygous for the S365C mutation (Fgfr3 365/+ ) exhibited skulls that were slightly dome-shaped (data not shown), which became progressively more pronounced as the mice aged ( Fig. 2A) . The skulls of Fgfr3 365/+ mice were markedly reduced in size along the anteroposterior axis, whereas they were slightly larger along the left-right and dorsal-ventral axes compared with wild-type animals ( Fig. 2A,  C-F) . The synochondroses of mutant mice had fused prematurely and ossified, resulting in a much shorter cranial base ( Fig. 2E and F) . The Fgfr3 365/+ mice exhibited severe dwarfism postnatally characterized by reduced length of the long bones, especially of femurs and tail bones ( Fig. 2A and B) . Some mutant animals manifested bowed tibias and fibulas ( Fig. 2A) , impairing their movement. The Fgfr3 363/+ animals also displayed longer incisors (not shown), possibly a consequence of the shortened cranial base that disrupts normal tooth alignment. The overgrown incisors were cut weekly allowing mutant mice to eat and drink normally. Under such conditions, some mutant mice survived for up to 6 months.
We investigated whether the Fgfr3 365/+ mice were fertile. Heterozygous animals at ages of 1.5-6 months were allowed to mate with other heterozygotes or with wild-type mice. All Fgfr3 365/+ males were infertile. Two of 10 Fgfr3 365/+ females that were mated with wild-type males each produced one litter of offspring; subsequent mating of the same pairs of animals failed to generate any more litters. The reduced fertility of the mutant mice is possibly due to their smaller size or to restrictions on their hindlimb movement, given that no abnormalities were apparent in their testes or ovaries (not shown).
Disorganized growth plates of Fgfr3 365/+ mutant mice
Histological examination of epiphyseal growth plates revealed differences between wild-type and mutant mice that were first apparent at embryonic day (E)17.5. Unlike the growth plates of wild-type animals, which exhibit distinct borders between each zone of chondrocytes (resting, proliferating, prehypertrophic and hypertrophic chondrocytes) (Fig. 3A) , growth plates of mutant mice showed no clear boundaries between these zones 3) exhibited, in addition to the wildtype fragment, a fragment of ∼9.4 kb. The targeting events were confirmed by digestion of genomic DNA with XbaI (Xb) and EcoRV (Ev) and Southern blot analysis with a 3′ internal probe (probe 2) (not shown) and sequencing analysis also verified the presence of the point mutation (not shown). Probe 1, a 1.9 kb SacII-BamHI fragment, and probe 2, a 1.65 kb SpeI-XbaI fragment, are 5′ flanking and 3′ internal to the targeting construct, respectively. (Fig. 3B ). Chondrocyte columns (longitudinal stacks of cells) were markedly shorter and hypertrophic chondrocytes were reduced in number in the growth plates of all mutant mice examined at ages between E17.5 and postnatal day (P)45 ( Fig. 3B , E and G; data not shown). Chondrocytes in the maturing zone were sometimes mingled with those in the hypertrophic zone of younger (<P20) mutant mice ( Fig. 3C-E ). Many histologically less well differentiated small spherical chondrocytes, some of which were directly opposed to the ossification front, invaded the hypertrophic zone ( Fig. 3C and D) . Conversely, prehypertrophic chondrocyte-like cells were often observed in resting or proliferating zones in Fgfr3 365/+ mice ( Fig. 3C-E ). These observations suggest that the FGFR3-S365C mutation uncouples the coordination between chondrocyte proliferation and differentiation. The growth plates of older (>P30) mutant animals ( Fig. 3G) were much narrower than age-matched controls ( Fig. 3F ) with fewer proliferating and hypertrophic chondrocytes, indicating that their activities had become minimal. (Fig. 4B) . The labeling intensity of mutant cells was also decreased. These observations suggest that the proliferative capacity of mutant chondrocytes is reduced compared with that of chondrocytes in wild-type littermates. We have previously shown that activated Fgfr3 signals activate Stats (3) (4) (5) . Consistently, Stat1 expression in the nuclei of mutant cells was more intense than in wild-type cells ( Fig. 4C and D) .
Reduced chondrocyte proliferation and differentiation in
In addition to proliferating, chondrocytes in the proliferation zone also undergo programmed differentiation into hypertrophic cells, a process characterized by a gradual increase in cell size while they move downward into the hypertrophic zone in the growth plate. Histologically, mutant chondrocytes appeared significantly smaller (Figs 3B and 4B) than wild-type cells (Figs 3A and 4A), indicating that the mutant cells were less well differentiated. Consistently, in situ hybridization using a probe for collagen type X gene, a specific marker for hypertrophic chondrocytes, revealed that the zone of hypertrophic chondrocytes was much narrower in mutant growth plates ( Fig. 4E and F) .
To further characterize the differentiation of mutant chondrocytes, we examined the expression of the IHH and PTHrP-R genes, specific markers of prehypertrophic chondrocytes. Expression of both genes was markedly downregulated, as reflected by reduced numbers of positive cells and signal intensity, in the mutant mice (Fig. 4G-L) . Together, these observations indicate that the FGFR3-S365C mutation impairs chondrocyte differentiation.
Downregulation of Ihh and PTHrP-R gene expression by bFGF in cultured bone
IHH, PTHrP and PTHrP-R contribute to a signaling pathway that plays essential roles in regulating chondrocyte proliferation and differentiation (25, 26) . The downregulation of Ihh and PTHrP-R gene expression in the growth plates of Fgfr3 365/+ mice is consistent with previous investigations showing that Ihh expression levels are lower in dwarf mice carrying activated FGFR3 (6, 24) . However, since the zones of chondrocytes that express Ihh and PTHrP-R in growth plates of all these mutant strains are narrower than those of control mice, it is not clear that the decreased expression of these genes is directly or indirectly caused by activated FGFR3. To distinguish this, we employed an embryonic bone culture system, in which bone growth and gene expression pattern can be monitored under defined conditions. We showed that the bone rudiments from E17.5 embryos had already initiated endochondral ossification, with a dark area in the center representing the zone of mineralized hypertrophic chondrocytes and light regions flanking the dark area corresponding to the zone of unmineralized hypertrophic chondrocytes (Fig. 5A) . The regions extending from the light areas to the ends of the bone represent proliferating and articular chondrocytes. Bone growth was revealed by increased total bone length and hypertrophic zone toward the ends of the rudiment after incubation for 3 days (Fig. 5A and B) . In the presence of bFGF (10 ng/ml), however, the increases in the lengths of the hypertrophic zone were greatly reduced ( and D), indicating inhibition of bone growth and chondrocyte differentiation. Quantitative analysis also revealed that the percentage increase in total bone length was reduced by bFGF treatment (Fig. 5G) . We next determined PTHrP-R and Ihh transcription levels by in situ hybridization at multiple time points. Our data revealed that the abundance of PTHrP-R and Ihh mRNAs in the bone rudiments was markedly reduced in the presence of bFGF for 36 h (Fig. 5E and F) . At this time point, no changes in bone growth were observed. Thus, PTHrP-R and Ihh downregulation precedes the appearance of bone abnormality and excludes the possibility that decreased expression of these genes is a consequence of bone dysplasia.
FGF-FGFR3 and PTHrP-PTHrP-R signals function independently in inhibiting chondrocyte differentiation
Overexpression of PTHrP or PTHrP-R inhibits chondrocyte differentiation (31) . Conversely, mice deficient in IHH, PTHrP or PTHrP-R exhibit premature chondrocyte hypertrophy (4, 25, 26) . However, the downregulation of PTHrP-R expression observed in Fgfr3 365/+ mice does not result in premature hypertrophy of chondrocytes. Alternatively, the decrease in PTHrPPTHrP-R signaling was not able to reverse the inhibition of chondrocyte differentiation induced by FGF-FGFR3 signaling. This observation suggests that FGF-FGFR3 signaling inhibits chondrocyte differentiation independently, irrespective of PTHrP-PTHrP-R signaling.
Therefore, we investigated whether the inhibition of chondrocyte differentiation by PTHrP-PTHrP-R signaling is dependent on FGF-FGFR3 signaling. Culture of bones from wild-type embryos in the presence of PTHrP markedly inhibited chondrocyte differentiation, as reflected in the reduced extent of the increase in the length of the hypertrophic zone (Fig. 6A-D, O) . This result is consistent with a previous observation that cultured bones from PTHrP knockout mice exhibit a marked hypertrophic expansion (32) .
Next, we examined bones isolated from Fgfr3 365/+ mice. Prior to culture, the mutant hypertrophic zone was much shorter than wild-type bone ( Fig. 6A and E) , indicating that the skeletal dysplasia caused by S365C mutation was apparent at this early developmental stage. The length of the hypertrophic zone of the mutant bone was increased by culture for 3 days, although to a reduced extent compared with the increases observed in wild-type bone (Fig. 6B, F and O) . This observation suggests that the S365C mutation did not completely activate the FGF-FGFR3 signaling pathway. As with wild-type bone, culture of bone from Fgfr3 365/+ mutant mice with PTHrP markedly reduced the extent of the increase in the length of the hypertrophic zone (Fig. 6E-H, O) , again indicating inhibition of chondrocyte differentiation by PTHrP. We also showed that PTHrP inhibited chondrocyte differentiation in cultures of bone isolated from FGFR3 knockout mice (Fig. 6K-O) . These data thus indicate that inhibition of chondrocyte differentiation by PTHrP is independent of FGFR3.
PTHrP increases the length of the proliferation zone but not the rate of chondrocyte proliferation in cultured bone
PTHrP induced increases in proliferation zone length in cultured wild-type and mutant bones (Fig. 6A-H) . In contrast, although bFGF reduced the extent of the increase in the size of the hypertrophic zone of wild-type bone, it had very little effect on the proliferation zone (Fig. 5A-D, G) . Because the chondrocyte proliferation rate was reduced in Fgfr3 365/+ mice, we examined whether the PTHrP-induced expansion of the proliferation zone was attributable to increased chondrocyte proliferation. However, we detected no marked difference in [ 3 H]thymidine incorporation between mutant bones cultured in the absence or presence of PTHrP (Fig. 6I and J) . PTHrPPTHrP-R signaling promotes the reversion of hypertrophic chondrocytes to prehypertrophic and proliferating cells (33) . It is thus possible that PTHrP treatment blocked chondrocyte differentiation and promoted reversion of hypertrophic cells to a less well-differentiated state. This effect would not only increase the pool of proliferating chondrocytes, but also prolong the time spent by cells in the proliferating state, thereby allowing them to undergo an increased number of cell divisions (without necessarily increasing their proliferation efficiency) before they enter the terminal differentiation pathway.
DISCUSSION
FGF-FGFR3 and IHH-PTHrP-PTHrP-R signaling pathways are important regulators of chondrocyte proliferation and differentiation during endochondral ossification (24, 25) . On the basis of the observation that IHH expression is markedly downregulated in mice that harbor activating mutations of FGFR3, it has been suggested that FGFR3 functions upstream of IHH and negatively regulates its expression. However, it has remained unclear whether FGF-FGFR3 signaling and IHHPTHrP-PTHrP-R signaling interact during bone growth. We have now provided additional evidence that activated FGFR3 signals downregulate expression of IHH, which is known to play an essential role in promoting chondrocyte proliferation (25) . In addition, we demonstrated that FGF-FGFR3 and PTHrP-PTHrP-R signals independently inhibit chondrocyte differentiation. On the basis of these observations, we propose that FGF-FGFR3 and IHH-PTHrP-PTHrP-R signals are transmitted by two integrated parallel pathways that perform both overlapping and distinct functions during long bone growth (Fig. 7) .
FGF-FGFR3 signaling targets STATs and IHH to inhibit chondrocyte proliferation
Mouse mutants harboring activating mutations of FGFR3 exhibit skeletal dysplasia characterized by reduced chondrocyte proliferation (5, 6, 24, 28) . It was shown that FGFR3 containing the TD-II mutation activates STAT1 in growth plate chondrocytes of TD-II patients, leading to upregulation of p21, a cell cycle inhibitor that blocks the G 1 -S transition (7). Activation of several STAT proteins, including STAT1, STAT5a and/or STAT5b, has also been detected in mouse models of achondroplasia that express activated forms of FGFR3 (5,6 and this study). Inhibition of bone growth by FGF has also been observed both with cultured bone (34) and in transgenic mice (35) ; such inhibition was not apparent with cultured bone isolated from STAT1-deficient mice (8) . These data thus support the notion that FGF-FGFR3 signaling inhibits bone growth through the activation of STAT proteins (Fig. 7) .
The downregulation of IHH and PTHrP-R gene expression apparent in Fgfr3 365/+ mice suggests a role for IHH and PTHrP signals in the pathogenesis of FGFR3-associated skeletal dysplasia. An essential role for IHH in chondrocyte proliferation and differentiation was recently revealed by the observation that IHH-deficient chondrocytes exhibit minimal proliferation and premature hypertrophy (25) . The expression of IHH in prehypertrophic chondrocytes was shown to induce expression of PTHrP in the articular perichondrium (4). The expression of PTHrP, in turn, results in activation of PTHrP-R in prehypertrophic chondrocytes (4) . The observation that expression of PTHrP was not detected in IHH-deficient articular perichondrium (25) is consistent with this view.
However, the absence of PTHrP signaling is only partially responsible for the skeletal phenotype of IHH-deficient mice (25) . The introduction of a constitutively active PTHrP-R into IHH-deficient mice failed to rescue either the short-limb dwarfism or the reduced chondrocyte proliferation apparent in these animals, although it prevented the premature chondrocyte hypertrophy (27) . These observations not only provide further evidence for a positive role of IHH signaling in regulating chondrocyte proliferation, but also suggest that IHH controls chondrocyte proliferation and differentiation in PTHrP-PTHrP-R-independent and -dependent manners, respectively.
FGF-FGFR3 and PTHrP-PTHrP-R signals inhibit chondrocyte differentiation independently
Our data show that the reduced chondrocyte differentiation in the growth plates of Fgfr3 365/+ mice and in bFGF-treated bone rudiments is accompanied by downregulation of PTHrP-R gene expression. These results suggest the possibility that reduced PTHrP-R expression is responsible for impaired chondrocyte differentiation. However, previous data obtained from both in vivo and in vitro studies are not consistent with this possibility since loss-of-function mutations in PTHrP or PTHrP-R result in premature hypertrophy of chondrocytes in mice (26, 36, 37) , and in cultured bone rudiments (32) . Thus, the activated FGF/FGFR3 signals appear to override the effect of reduced PTHrP signaling on chondrocyte differentiation. We also considered the possibility that FGF-FGFR3 signaling functions downstream of PTHrP-PTHrP-R. However, we showed that the effect of PTHrP treatment on chondrocyte differentiation is independent of FGFR3, irrespective of FGFR3 mutation status. Given that both FGF-FGFR3 and PTHrP-PTHrP-R signals are dominant, we propose that these signals function independently in repressing chondrocyte differentiation (Fig. 7) . According to this model, the joint action of both signals would be predicted to exert a more marked inhibitory effect than either signal alone. Consistently, PTHrP treatment further inhibited chondrocyte differentiation in Fgfr3 365/+ mutant bones.
Achondroplasia, not lethal dwarfism, is associated with the S365C mutation of FGFR3 in mice
The S371C mutation in human FGFR3 results in TD-I, a neonatally lethal skeletal dysplasia (20) . However, the corresponding S365C mutation in mouse FGFR3 is not lethal, exhibiting a markedly less severe skeletal phenotype. This phenotypic discrepancy could be attributed to multiple factors. First, different genetic backgrounds can give rise to markedly different phenotypes (38, 39) . Although individuals with TD-I usually die at birth, some survive for many years (16, 40) . Given that humans are heterogeneous, epigenetic factors may affect TD-I severity. Second, the severity of skeletal phenotype is approximately proportional to the level of activation of various FGFR3 mutants (22) . We have previously shown that the S365C mutation of FGFR3 results in a much lower level of receptor tyrosine kinase activity than does K650E, a TD-IIassociated mutation that causes neonatal death both in humans (5) and in mouse when it is expressed properly (41). These observations suggest that the S365C mutation of mouse FGFR3 is relatively weak in terms of its effect on FGFR3 activity, possibly explaining its associated mild phenotype.
Although Fgr3 365/+ mice survive at birth, they exhibit a phenotype more severe than other achondroplastic mice generated previously in our laboratory (5, 6) . They manifested an embryonic onset of skeletal dysplasia as well as bowed tibia in older animals. They also exhibited a high postnatal mortality, with many animals dying between 1 week and 6 months of age. All of the described TD patients that survived after birth died before reaching 10 years of age (16, 42, 43) . The Fgr3 365/+ mice might therefore represent a model for such surviving individuals with severe achondroplasia. These animals together with the other FGFR3 mutant mice created previously represent a spectrum of skeletal dysplasia encompassing severe, intermediate and mild forms of dwarfism that mimic various forms of human FGFR3-associated disease. They should therefore prove useful as models for studying the mechanisms that underlie the human diseases as well as for the development of new therapeutic strategies.
MATERIALS AND METHODS
Site-directed mutagenesis and targeting vector construction
The S365C mutation was introduced into exon 10 of the mouse Fgfr3 gene with the use of the oligonucleotide 5′-GGAAACTG-ATGAGGCTGGCTGCGTGTACGCAGGCGTCCTCAGC-3′ (underline indicates the mutated nucleotide) and a standard protocol for site-directed mutagenesis. The targeting vector was constructed with the use of Fgfr3 genomic DNA isolated previously (3). A 2.8 kb EcoRI-SmaI fragment of Fgfr3 genomic DNA containing the S365C mutation was inserted into the EcoRI and BamHI sites of the pLoxpneo vector (44) . The resulting plasmid was digested with HpaI and NotI, and a 3.9 kb SmaI-XbaI fragment of Fgfr3 genomic DNA was inserted. The resulting targeting construct, pFgfr3-S365C, is shown in Figure 1A .
Homologous recombination in ES cells and generation of germ-line chimeras
Mouse TC1 embryonic stem (ES) cells (3) were transfected with NotI-digested pFgfr3-S365C. Genomic DNA from resulting G418-and FIAU-resistant ES cell clones was digested with restriction enzymes and subjected to Southern blot analysis with a 5′ flanking (Fig. 1B) or a 3′ internal (not shown) probe specific for Fgfr3. Blastocyst injection and screening for germ-line transmission were performed according to standard procedures.
Genotype analysis
Mice exhibiting germ-line transmission of the S365C mutation were crossed with EIIa-Cre mice (37) in order to delete the neo gene. Genotypes of the resulting progeny were determined by polymerase chain reaction analysis with primers 1 (5′-CCGG-GGGAAAGCTTGAAAA-3′) and 2 (5′-TGTAAAAGGGGT-GGGGTGGTAG-3′), which flank the SmaI site and amplify DNA fragments of 534 and 594 bp from wild-type and mutant Fgfr genes, respectively. The mutant fragment is larger because of the presence of a LoxP site.
Histology and skeletal staining
Histological sections (5 µm) were prepared from selected tissues that had been fixed in 10% formalin, decalcified by incubation with 15% EDTA at 4°C for 1 week, and embedded in paraffin. Skeletal staining with Alizarin red S and Alcian blue was performed as described (45) .
In situ hybridization and [ 3 H]thymidine labeling
In situ hybridization was performed according to standard procedures with probes listed in the Acknowledgements section. [ 3 H]thymidine (Amersham Pharmacia Biotech) was injected intraperitoneally at a dose of 20 µCi/g of body weight and animals were killed 2 h later. Slides were dipped in emulsion (Kodak NTB-2) and exposed for 4 to 15 days before developing.
Culture of embryonic metatarsal rudiments
Culture of metatarsal rudiments isolated from 17.5-day pregnant mice was performed as described (32) . PTHrP (0.1 µM) (Sigma) or bFGF (10 ng/ml) (Sigma) dissolved in 4 mM HCl was added to cultures after 16-20 h. The culture medium was changed on the second day of culture with PTHrP or bFGF. The total length and hypertrophic zone length were measured with an eyepiece scale of a Leica dissecting microscope. Changes in length were expressed as percentage increase relative to the value before treatment. Data are expressed as means ± SD, and the significance of differences was evaluated with Student's t-test.
